Go Deep
Inhibrx Biosciences, Inc.
Inhibrx Biosciences, Inc. Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | -43,374 | -9.8 | -24.19 | 13.39 | 8,292.95 |
| Oct 2026 | -43,063 | -9.6 | -23.69 | 13.39 | 8,095.22 |
| Oct 2026 | -43,960 | -10.4 | -25.14 | 13.39 | 8,593.97 |
| Oct 2026 | -43,845 | -10.1 | -24.96 | 13.39 | 8,508.24 |
| Oct 2026 | -43,838 | -10.1 | -24.95 | 13.39 | 8,513.56 |
| Oct 2026 | -44,782 | -10.7 | -26.48 | 13.39 | 9,036.00 |
| Oct 2026 | -45,277 | -11.1 | -27.28 | 13.39 | 9,287.02 |
| Oct 2026 | -45,090 | -10.9 | -26.98 | 13.39 | 9,165.35 |
Inhibrx Biosciences, Inc. Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 |
|---|---|---|---|---|
| Revenue | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Profit | -36,650,000.0 | -33,441,000.0 | -32,834,000.0 | -35,256,000.0 |
| EPS | -2.3 | -2.1 | -2.1 | -2.3 |
Inhibrx Biosciences, Inc. Revenue & Profit: Last 4 Years
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Revenue | 1,300,000.0 | 200,000.0 | 1,800,000.0 | 1,301,000.0 |
| Net Profit | -140,055,000.0 | 1,687,572,000.0 | -241,361,000.0 | -115,325,000.0 |
| EPS | -9.0 | 114.0 | -16.9 | -8.1 |
Inhibrx Biosciences, Inc. Balance Sheet
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Total Assets | 146,478,000.0 | 180,767,000.0 | 307,893,000.0 | 16,645,000.0 |
| Total Liabilities | 138,485,000.0 | 47,183,000.0 | 264,390,000.0 | 23,945,000.0 |
| Total Equity | 7,993,000.0 | 133,584,000.0 | 43,503,000.0 | -7,300,000.0 |
Owes vs Owns
Inhibrx Biosciences, Inc. owed $1.34 for every $1 it owned in Jun 2026, down from $1.44 in Dec 2022.
| Period | Jun 2026 | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
| Owes vs Owns | 1.34× | 0.95× | 0.26× | 0.86× | 1.44× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Inhibrx Biosciences, Inc. Assets & Liabilities Breakdown (USD millions)
What it owns — Dec 2025
Cash & short-term investments 84.8%Fixed assets (tangible) 6.3%Other assets 8.7%
How it's funded — Dec 2025
Short-term debt 1.6%Long-term debt 68.7%Payables 4.1%Other liabilities 20.2%Shareholders' equity 5.5%
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 124.2 | 152.6 | 277.9 | 0.0 |
| Receivables | 0.2 | 0.4 | 0.8 | 0.3 |
| Inventory | 0.0 | 0.0 | 0.0 | 0.0 |
| Fixed assets (tangible) | 9.3 | 13.5 | 9.4 | 7.2 |
| Intangible assets | 0.0 | 0.0 | 0.0 | 0.0 |
| Long-term investments | 0.0 | 0.0 | 0.0 | 0.0 |
| Other assets | 12.8 | 14.2 | 19.8 | 9.2 |
| Liabilities & equity | ||||
| Short-term debt | 2.3 | 1.6 | 2.1 | 1.9 |
| Long-term debt | 100.6 | 6.5 | 207.0 | 3.2 |
| Payables | 5.9 | 9.2 | 11.0 | 4.3 |
| Other liabilities | 29.7 | 29.9 | 44.4 | 14.6 |
| Shareholders' equity | 8.0 | 133.6 | 43.5 | -7.3 |
| Net tangible assets | 8.0 | 133.6 | 43.5 | -7.3 |
Inhibrx Biosciences, Inc. Cash Flow
| Line Item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|
| Operating Activities | -129,794,000.0 | -194,409,000.0 | -193,309,000.0 | -90,811,000.0 |
| Investing Activities | -28,000.0 | -2,597,000.0 | -4,593,000.0 | -686,000.0 |
| Financing Activities | 101,446,000.0 | 71,678,000.0 | 201,961,000.0 | 91,497,000.0 |